Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.992
+0.011 (1.16%)
At close: Dec 5, 2025, 4:00 PM EST
0.975
-0.017 (-1.71%)
After-hours: Dec 5, 2025, 6:58 PM EST
Oncolytics Biotech Employees
Oncolytics Biotech had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change
-1
Growth
-3.45%
Revenue / Employee
n/a
Profits / Employee
-$904,312
Market Cap
105.31M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ONCY News
- 15 days ago - Oncolytics Biotech® Provides Update on Special Meeting of Shareholders - Business Wire
- 16 days ago - Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer - Business Wire
- 5 weeks ago - Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care - PRNewsWire
- 6 weeks ago - Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada - PRNewsWire
- 2 months ago - Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study - PRNewsWire
- 2 months ago - Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion - PRNewsWire
- 3 months ago - Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions - PRNewsWire
- 3 months ago - Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors - PRNewsWire